These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28061986)

  • 1. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
    Kazandjian D; Landgren O
    Semin Oncol; 2016 Dec; 43(6):682-689. PubMed ID: 28061986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Drugs in Multiple Myeloma.
    Kunacheewa C; Orlowski RZ
    Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pharmacotherapy options for multiple myeloma.
    Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
    Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel targeted therapy in multiple myeloma].
    Izumi T
    Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for multiple myeloma.
    Wallington-Beddoe CT; Pitson SM
    Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
    [No Abstract]   [Full Text] [Related]  

  • 15. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
    Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P
    Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
    Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
    Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
    Harada T; Hideshima T; Anderson KC
    Int J Hematol; 2016 Sep; 104(3):300-9. PubMed ID: 27099225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of novel agents in multiple myeloma patients with hepatic impairment.
    Stansfield LC; Gonsalves WI; Buadi FK
    Future Oncol; 2015; 11(3):501-10. PubMed ID: 25675129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
    McCullough KB; Hobbs MA; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2018 Apr; 13(2):114-124. PubMed ID: 29450683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.